Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 6 | 2022 | 24 | 3.520 |
Why?
|
| Pharmacists | 10 | 2023 | 56 | 3.400 |
Why?
|
| Pharmacy | 5 | 2023 | 34 | 2.880 |
Why?
|
| Pharmaceutical Services | 5 | 2023 | 23 | 2.520 |
Why?
|
| Pharmacies | 3 | 2023 | 23 | 2.250 |
Why?
|
| Students, Pharmacy | 3 | 2025 | 57 | 2.080 |
Why?
|
| Atrial Fibrillation | 6 | 2018 | 121 | 1.710 |
Why?
|
| Professional Role | 6 | 2022 | 40 | 1.640 |
Why?
|
| Pulmonary Embolism | 4 | 2018 | 38 | 1.290 |
Why?
|
| Asthma | 4 | 2020 | 410 | 1.190 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 176 | 1.130 |
Why?
|
| Telemedicine | 2 | 2020 | 215 | 1.020 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 309 | 1.000 |
Why?
|
| Humans | 45 | 2025 | 42163 | 0.900 |
Why?
|
| Civil Defense | 1 | 2025 | 16 | 0.900 |
Why?
|
| Disaster Planning | 1 | 2025 | 58 | 0.860 |
Why?
|
| Stroke | 5 | 2018 | 348 | 0.770 |
Why?
|
| Case Management | 1 | 2022 | 24 | 0.750 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.750 |
Why?
|
| Warfarin | 3 | 2018 | 66 | 0.740 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 24 | 0.710 |
Why?
|
| Research Personnel | 1 | 2023 | 191 | 0.700 |
Why?
|
| Health Care Costs | 2 | 2019 | 89 | 0.700 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2020 | 5 | 0.680 |
Why?
|
| Hospital Mortality | 3 | 2017 | 206 | 0.670 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 51 | 0.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 744 | 0.640 |
Why?
|
| Ambulatory Care | 1 | 2020 | 81 | 0.630 |
Why?
|
| Drugs, Generic | 1 | 2019 | 6 | 0.620 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 9 | 0.620 |
Why?
|
| Prescription Drugs | 1 | 2019 | 32 | 0.600 |
Why?
|
| Internship and Residency | 1 | 2020 | 141 | 0.600 |
Why?
|
| Benzazepines | 2 | 2016 | 33 | 0.600 |
Why?
|
| Social Values | 1 | 2018 | 31 | 0.590 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 532 | 0.570 |
Why?
|
| United States | 11 | 2023 | 5072 | 0.570 |
Why?
|
| Stroke Volume | 2 | 2016 | 122 | 0.570 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 26 | 0.550 |
Why?
|
| Glucosides | 1 | 2017 | 21 | 0.540 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 25 | 0.540 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 73 | 0.540 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 47 | 0.530 |
Why?
|
| Quality of Life | 2 | 2020 | 599 | 0.530 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 49 | 0.530 |
Why?
|
| Observation | 1 | 2017 | 10 | 0.530 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2016 | 14 | 0.510 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 60 | 0.510 |
Why?
|
| Hospitalization | 2 | 2018 | 482 | 0.510 |
Why?
|
| Resource Allocation | 1 | 2016 | 14 | 0.490 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 729 | 0.490 |
Why?
|
| Patient Admission | 1 | 2016 | 50 | 0.480 |
Why?
|
| Thiazoles | 1 | 2016 | 76 | 0.480 |
Why?
|
| Pyridones | 1 | 2016 | 50 | 0.470 |
Why?
|
| Tetrazoles | 1 | 2015 | 45 | 0.470 |
Why?
|
| Pyrazoles | 1 | 2016 | 93 | 0.470 |
Why?
|
| Databases, Factual | 1 | 2017 | 336 | 0.470 |
Why?
|
| Pyridines | 1 | 2016 | 134 | 0.460 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 115 | 0.440 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3077 | 0.440 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2016 | 93 | 0.430 |
Why?
|
| Aged | 11 | 2024 | 7982 | 0.420 |
Why?
|
| Treatment Outcome | 6 | 2018 | 1586 | 0.420 |
Why?
|
| Smoking Cessation | 1 | 2020 | 583 | 0.410 |
Why?
|
| Idaho | 3 | 2024 | 5 | 0.400 |
Why?
|
| Heart Failure | 1 | 2015 | 298 | 0.370 |
Why?
|
| Workflow | 2 | 2021 | 23 | 0.350 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2020 | 22 | 0.340 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2020 | 8 | 0.330 |
Why?
|
| Female | 17 | 2024 | 24018 | 0.320 |
Why?
|
| Male | 15 | 2024 | 22779 | 0.310 |
Why?
|
| Anticoagulants | 4 | 2018 | 121 | 0.290 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2018 | 45 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 62 | 0.280 |
Why?
|
| Markov Chains | 2 | 2018 | 42 | 0.270 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 76 | 0.260 |
Why?
|
| Chronic Disease | 2 | 2023 | 541 | 0.250 |
Why?
|
| Risk Assessment | 6 | 2018 | 845 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 225 | 0.240 |
Why?
|
| Curriculum | 2 | 2025 | 311 | 0.230 |
Why?
|
| Prospective Studies | 3 | 2018 | 1574 | 0.220 |
Why?
|
| Educational Measurement | 1 | 2025 | 100 | 0.220 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 249 | 0.220 |
Why?
|
| Educational Status | 2 | 2023 | 335 | 0.220 |
Why?
|
| Education, Pharmacy | 1 | 2025 | 56 | 0.220 |
Why?
|
| Middle Aged | 6 | 2024 | 11819 | 0.210 |
Why?
|
| Empyema, Pleural | 1 | 2022 | 2 | 0.190 |
Why?
|
| Pleural Effusion | 1 | 2022 | 8 | 0.190 |
Why?
|
| Pleural Diseases | 1 | 2022 | 3 | 0.190 |
Why?
|
| Credentialing | 1 | 2022 | 3 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 233 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2022 | 55 | 0.180 |
Why?
|
| Dietetics | 1 | 2022 | 23 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 47 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2485 | 0.180 |
Why?
|
| Rural Population | 1 | 2024 | 352 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2022 | 143 | 0.170 |
Why?
|
| Medicare | 2 | 2021 | 326 | 0.170 |
Why?
|
| Authorship | 1 | 2020 | 5 | 0.170 |
Why?
|
| Washington | 1 | 2020 | 36 | 0.170 |
Why?
|
| Oregon | 1 | 2020 | 64 | 0.170 |
Why?
|
| New Mexico | 1 | 2020 | 36 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 10 | 0.170 |
Why?
|
| Bibliometrics | 1 | 2020 | 15 | 0.170 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 18 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2023 | 526 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 24 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2020 | 152 | 0.160 |
Why?
|
| Mass Screening | 1 | 2024 | 531 | 0.160 |
Why?
|
| Health Personnel | 1 | 2022 | 262 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 94 | 0.150 |
Why?
|
| Adult | 5 | 2024 | 13458 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 708 | 0.150 |
Why?
|
| Crataegus | 1 | 2018 | 2 | 0.140 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 11 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 27 | 0.140 |
Why?
|
| Thrombectomy | 1 | 2018 | 12 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 358 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2018 | 29 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 35 | 0.140 |
Why?
|
| Drug Costs | 1 | 2017 | 36 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 97 | 0.140 |
Why?
|
| Oculomotor Nerve | 1 | 2017 | 4 | 0.130 |
Why?
|
| Oculomotor Muscles | 1 | 2017 | 14 | 0.130 |
Why?
|
| Eye Movements | 1 | 2017 | 16 | 0.130 |
Why?
|
| Electrocardiography | 1 | 2018 | 184 | 0.130 |
Why?
|
| Neoplasms | 2 | 2018 | 1341 | 0.130 |
Why?
|
| Amiodarone | 1 | 2016 | 2 | 0.130 |
Why?
|
| Heart | 1 | 2018 | 181 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2803 | 0.130 |
Why?
|
| Public Health | 1 | 2020 | 405 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2016 | 54 | 0.120 |
Why?
|
| Recurrence | 1 | 2016 | 149 | 0.120 |
Why?
|
| Immune System Diseases | 1 | 2016 | 21 | 0.120 |
Why?
|
| Neprilysin | 1 | 2015 | 8 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2018 | 196 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 438 | 0.120 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 52 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 78 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2015 | 102 | 0.120 |
Why?
|
| Physicians | 1 | 2017 | 180 | 0.120 |
Why?
|
| Risk Factors | 3 | 2018 | 3942 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2018 | 303 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 261 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 638 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 725 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 177 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2018 | 1729 | 0.110 |
Why?
|
| Child | 1 | 2022 | 3381 | 0.110 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 1 | 0.100 |
Why?
|
| Young Adult | 3 | 2024 | 4936 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 568 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 1848 | 0.090 |
Why?
|
| Adolescent | 2 | 2024 | 5950 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 2012 | 369 | 0.080 |
Why?
|
| Vaccination | 2 | 2022 | 332 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2018 | 92 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 850 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 1054 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 163 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 25 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 26 | 0.050 |
Why?
|
| Health Occupations | 1 | 2021 | 17 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 41 | 0.040 |
Why?
|
| Alaska | 1 | 2020 | 61 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 222 | 0.040 |
Why?
|
| Faculty | 1 | 2020 | 105 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 143 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 173 | 0.040 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2018 | 5 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 61 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 112 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 72 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 157 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 305 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 362 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 149 | 0.030 |
Why?
|
| Motor Neurons | 1 | 2017 | 88 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 223 | 0.030 |
Why?
|
| Axons | 1 | 2017 | 116 | 0.030 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2016 | 20 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 58 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 431 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 153 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 157 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 256 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1139 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1051 | 0.030 |
Why?
|
| Students | 1 | 2021 | 617 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 164 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 6490 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 242 | 0.030 |
Why?
|
| Facial Pain | 1 | 2012 | 3 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2012 | 14 | 0.020 |
Why?
|
| Trigeminal Nuclei | 1 | 2012 | 11 | 0.020 |
Why?
|
| Nociceptors | 1 | 2012 | 29 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 82 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 928 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 16695 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 1804 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 1554 | 0.020 |
Why?
|